#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pyruvate dehydrogenase complex deficiency Cortical dysplasia Ductal adenocarcinoma of pancreas Pouchitis Transplant rejection Neurodevelopmental disorder Neuroendocrine carcinoma metastatic Undifferentiated sarcoma Wolfram syndrome Phaeochromocytoma Atopic keratoconjunctivitis Pleomorphic liposarcoma Dupuytren's contracture Polycystic liver disease Immunodeficiency congenital More trials…

    Learn about Rare Diseases

    X-linked lymphoproliferative syndrome – Basic Information Pulmonary fibrosis – Trials in Disease Loeys-Dietz syndrome – Trials in Disease Angiosarcoma recurrent – Trials in Disease Langerhans’ cell histiocytosis – Diagnostics Haemophilia A without inhibitors – Life with Disease Retinoblastoma – Diagnostics Erdheim-Chester disease – Life with Disease Angiosarcoma recurrent Antisynthetase syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Jk08 Ruzasvir Platelet Concentrate Etravirine Netupitant LY3841136 SODIUM Pegargiminase Tetrahydrouridine Mavorixafor Dabrafenib Eliglustat Tartrate Rucaparib TAZAROTENE Linperlisib ATIGOTATUG Hexaminolevulinate Air, Medicinal Sodium Acetate (1-13C) IHMA-2121771-1 Povidone More therapies…

    Learn about Your Condition

    Colorectal cancer Non-obstructive cardiomyopathy Milk allergy Renal cancer metastatic Cardiovascular disorder Agitation postoperative Oesophageal disorder CDKL5 deficiency disorder Angelman's syndrome Nasal sinus cancer Diabetic gastroparesis Radius fracture Hyperhidrosis Bone hypertrophy Limb reduction defect More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone-refractory prostate cancer

  • Study of Darolutamide and Testosterone for Patients with Advanced Prostate Cancer Resistant to Standard Hormone Therapy

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Testosterone
    • Abiraterone
    • Darolutamide
    Germany

  • Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ifinatamab Deruxtecan
    • Betamethasone Sodium Phosphate
    • Buclizine Hydrochloride
    Austria Czechia Denmark France Germany Greece +7

  • Study on Adding Darolutamide to First-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer Using a Drug Combination

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Lutetium (177Lu) Oxodotreotide
    • Radium Ra 223 Dichloride
    • Cabazitaxel
    Spain

  • Study on Cannabidiol for Pain Relief in Patients with Advanced Prostate Cancer

    Recruiting

    2 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Cannabidiol
    Denmark

  • Study of ETX-19477 for Patients with Advanced Solid Tumors After Standard Treatment

    Recruiting

    2 1 1
    Investigated Drugs:
    • ETX-19477
    France Italy Spain

  • Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    • Prostate cancer metastatic
    Investigated Drugs:
    • 5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
    • Enzalutamide
    Bulgaria Czechia Denmark Finland France Germany +8
Previous Page
1 2 3 4 … 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!